Haihua Z. Qian
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Intranuclear paraspeckle-circular RNA TACC3 assembly forms RNA-DNA hybrids to facilitate MASH-related hepatocellular carcinoma growth in an m6A-dependent manner.
Journal: Cancer communications (London, England)
Published: January 23, 2025
Circular RNA CDYL facilitates hepatocellular carcinoma stemness and PD-L1+ exosomes-mediated immunotherapy resistance via stabilizing hornerin protein by blocking synoviolin 1-mediated ubiquitination.
Journal: International journal of biological macromolecules
Published: January 17, 2025
N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes.
Journal: iScience
Published: January 28, 2023
miR-2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: November 09, 2021
PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma.
Journal: Cell & bioscience
Published: August 10, 2021
Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Cancer Letters 337 (2013) 226-236].
Journal: Cancer letters
Published: January 27, 2020
Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Canc. Lett. 337 (2013) 226-236].
Journal: Cancer letters
Published: January 14, 2020
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma.
Journal: Cancer letters
Published: January 11, 2018
I131 reinforces antitumor activity of metuximab by reversing epithelial-mesenchymal transition via VEGFR-2 signaling in hepatocellular carcinoma.
Journal: Genes to cells : devoted to molecular & cellular mechanisms
Published: August 21, 2017
Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
Journal: Oncotarget
Published: December 10, 2015
Last Updated: 09/26/2026